In a nutshell This study aimed to investigate treatments and outcomes for patients with relapsed or unresponsive nodular lymphocyte-predominant Hodgkin lymphoma. This study concluded that these patients have a good overall prognosis and treatments should be chosen individually. Some background Radiotherapy (RT), chemotherapy (CT) and rituximab...
Read More
In a nutshell This study evaluated the long-term outcomes of patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL) after undergoing radiation, chemotherapy, and autologous stem cell transplantation (autoSCT). This study concluded that total lymphoid irradiation (TLI) therapy before a bone marrow transplant can improve...
Read More
In a nutshell This study investigated the effectiveness of the combined treatment FOLFIRI with aflibercept (Zaltrap) outside of clinical trials in patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment might be a safe second line option in patients who progressed after first-line...
Read More
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read More
In a nutshell This study evaluated the safety and effectiveness of PD-1 inhibitors for patients with classical Hodgkin lymphoma (cHL) outside of clinical trials. This study concluded that PD-1 inhibitors are safe and effective for these patients. Some background Standard first-line chemotherapy is highly effective in treating 70 – 80% of...
Read More
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with leukemia/lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect...
Read More
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads...
Read More
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads to...
Read More
In a nutshell This study examined if nivolumab is an effective treatment for relapsed and unresponsive Hodgkin lymphoma. This study concluded that nivolumab is an effective treatment for these patients, regardless of previous stem cell treatment status. Some background Standard treatment for patients with Hodgkin lymphoma (HL) which has relapsed or...
Read MoreIn a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive chronic lymphocytic leukemia (CLL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in relapsed/unresponsive CLL. Some background...
Read MoreIn a nutshell This trial aims to look at how safe and effective a new combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda). The main outcome measured will be the number of patients who respond to treatment, and to what extent they respond. This study is being conducted in Spain, Sweden, and the United States. The details...
Read More
